Anlong Bio Announces IND Approval for ABA001, a Novel Twice-Yearly Injectable siRNA Therapy for Hypertension

Beijing News reported that, according to the WeChat Official Account "Beijing Shunyi," recently, ABA001, an innovative hypertension drug co-developed by Anlong (Beijing Anlong Biomedical Co., Ltd.), a company based in Shunyi, received the clinical trial approval notice from the National Medical Products Administration. This marks a new exploration in the field of long-acting hypertension treatment in China.

Hypertension is one of the most common chronic diseases in China, and poor long-term control can easily lead to cardiovascular and cerebrovascular diseases. Currently, mainstream antihypertensive drugs used in clinical practice all require daily administration, and patients often experience blood pressure fluctuations due to missed doses, which affects efficacy.

ABA001 is a novel antihypertensive drug with complete independent intellectual property rights, fully developed by Anlong.SunNovoIn-depth cooperative development. The product is based on innovative molecular design and sustained-release technology, aiming to achieve an ultra-long dosing cycle and stable blood drug concentration, breaking through the limitations of traditional drugs that require daily administration.

"Traditional antihypertensive drugs need to be taken daily. When taken, blood pressure drops, but if stopped, it rises again. However, our innovative small nucleic acid drug ABA001 can maintain stable blood pressure for half a year with just one injection," said Zhao Chunlin, founder of Beijing Anlong Biomedical Co., Ltd. "This will greatly improve medication adherence, achieve steady blood pressure control, and fundamentally enhance treatment outcomes and patients' quality of life."

Next, Shunyi District will continue to optimize the business environment to assist Anlong in efficiently advancing the ABA001 clinical trial. If the drug is approved for marketing, it is expected to fill the market gap for long-acting antihypertensive drugs, providing a more convenient, safer, and longer-lasting "Shunyi solution" for hypertensive patients across China. This will also inject new momentum into the development of Shunyi District's biopharmaceutical industry cluster and the construction of "Healthy Shunyi."

Editor: Zhang Lei